Clinical Research Tools: A Special Situation for Venture Investors and Entrepreneurs
This article was originally published in Start Up
Executive Summary
Five years after the genomics bubble burst and financing doors shut, a small window may be opening for research tool suppliers that help pharma improve R&D efficiency and cost structure. But clinically-oriented research companies face particular challenges, notably how to build a business where customer adoption is slow but technology is evolving rapidly and investors are impatient.
You may also be interested in...
Can Anyone Make Money from Biomarkers?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.
The Challenge of Making Money from Biomarkers
VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model
The Challenge of Making Money from Biomarkers
VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model